Guest Post by David Kliff, Diabetic Investor
The FDA approved Dexcom’s request for a non-adjunctive claim this week. It looks like a bad situation for conventional glucose monitors, and believe it or not is about to get worse. Here’s why.

In the fasting state, hyperglycemia is directly related to: 1. Increased hepatic glucose production 2. Defective insulin stimulation of target tissue glucose disposal 3. Decreased adipocyte lipolysis 4. Loss of pancreatic α-cell functionality Did you get it right? Follow the link to find out!

Do you promote the use of metformin to help prevent cancer as well as to control blood sugars? Follow the link to share your opinion and see what your colleagues think!

The dust has settled from the ADA scientific sessions in New Orleans and we have had time to look at what we learned about SGLT-2 Inhibitors. There were at least 40 posters on how they work and what they can do, but there was not a whole lot about clinical use. …

Over the last 7 years we have heard all about the benefits of GLP-1 analogs. One of the benefits that is often touted is the increase in first phase insulin release. In simple terms, we define this as “the quick release of insulin at the first bite of food,” but …

Male, 26 years of age, type 2 diabetes, obesity, hyperlipidemia, hypertension. Strong family history of type 2 diabetes with complications. Has been a patient since diagnosed 2 years ago. Has met with dietitian. Hasn’t made dietary changes, increased activity, or taken meds prescribed to lower his glucose. A1C 9.2% and rising every 3 months. He would also miss many of his appointments. Stated, “Nothing is going to bother me. Maybe it did my family, but that was a different time and it’s not going to happen to me. I’m going to go on enjoying my life.”

In part 1 of this Exclusive Interview, Kimberly Ward explains the goal and use of the Accu-Chek Connect System.

In this week's Homerun Slides, the principles of the AACE/ACE comprehensive type 2 diabetes management algorithm.

Dynamics of insulin secretion: Biphasic insulin secretion -- insulin release from pancreatic beta cells in response to glucose is characterized by biphasic kinetics: an initial component (1st phase), which develops rapidly but lasts only a few minutes, followed by a sustained component (2nd phase). It has been thought that the biphasic response of insulin secretion reflects primarily the dynamics of spatially and functionally distinct insulin granules. The prevailing hypothesis is that the 1st phase of insulin secretion is attributable to fusion of predocked granules from a readily releasable pool (RRP) that accounts for less than 5% of total granules, while the 2nd phase involves recruitment of granules from a more distant reserve pool (RP) that accounts for the great majority of total granules.

When I was was doing a lot of diabetes management and pump starts, U-500 was always a fear causer for many medical professionals. Part of this came from problems with the conversion from a U-100 dose to an equivalent U-500 dose. Even though you simply divided the unit dose by …